Community-Acquired Pneumonia (eBook)
286 Seiten
Wiley (Verlag)
978-0-470-77278-2 (ISBN)
Following a description of the epidemiology and microbial etiology of ambulatory and hospitalized CAP, this book provides an in-depth review of the important new advances in therapeutics, including management of drug resistance to the three major classes of antibiotics used for treatment of CAP: ?-lactams, macrolides and quinolones. All of them have advantages and disadvantages and these are put into perspective. This book highlights guideline recommendations and presents a balanced analysis to help physicians deliver the highest standard of care. In addition, the authors provide an insight into the 10% of patients who do not respond to antibiotics and could benefit from adjunctive therapies, some still under review.
This volume will be welcomed by pulmonologists and all clinicians involved in managing community-acquired pneumonia.
Dr. Antoni Torres, Cap de Servei de Pneumologia i Al'lèrgia Respiratria, Hospital Clínic de Barcelona, BARCELONA, SPAIN; Chairman, ERS Task Force on European Guidelines on hospital acquired pneumonia; Head, ERS Scientific Assembly on Respiratory Infections.
Dr Rosario Menéndez, Hospital Clínic de Barcelona, BARCELONA, SPAIN.
Community-Acquired Pneumonia (CAP) refers to pneumonia acquired outside of hospitals or extended-care facilities, and is distinct from Nosocomial or hospital-acquired pneumonia, which is a separate disease entity. It is one of the most common respiratory infections and presents one of the major health problems today, with an incidence that ranges from eight to fifty cases per thousand individuals each year. Mortality is still very high and yet the risk factors are very well known. Many of these are related to antibiotic treatment; delay in administration, inadequacy of empiric antibiotics and lack of adherence to guidelines for treatment are all clearly associated with poor treatment outcomes. Following a description of the epidemiology and microbial etiology of ambulatory and hospitalized CAP, this book provides an in-depth review of the important new advances in therapeutics, including management of drug resistance to the three major classes of antibiotics used for treatment of CAP: -lactams, macrolides and quinolones. All of them have advantages and disadvantages and these are put into perspective. This book highlights guideline recommendations and presents a balanced analysis to help physicians deliver the highest standard of care. In addition, the authors provide an insight into the 10% of patients who do not respond to antibiotics and could benefit from adjunctive therapies, some still under review. This volume will be welcomed by pulmonologists and all clinicians involved in managing community-acquired pneumonia.
Dr. Antoni Torres, Cap de Servei de Pneumologia i Al'lèrgia Respiratria, Hospital Clínic de Barcelona, BARCELONA, SPAIN; Chairman, ERS Task Force on European Guidelines on hospital acquired pneumonia; Head, ERS Scientific Assembly on Respiratory Infections. Dr Rosario Menéndez, Hospital Clínic de Barcelona, BARCELONA, SPAIN.
Community-Acquired Pneumonia 3
Contents 7
Preface 9
List of Contributors 11
1 Epidemiology of Community-Acquired Pneumonia Outside Hospital 13
2 Epidemiology of Adult Hospitalized Community-Acquired Pneumonia 17
3 Microbial Aetiology and Antibiotic Resistances in Community-Acquired Pneumonia 33
4 Microbiological Diagnosis of Community-Acquired Pneumonia 55
5 Empirical Treatment of Community-Acquired Pneumonia: Current Guidelines 75
6 Pathogen Directed Antimicrobial Treatment of Pneumonia 113
7 General Pharmacological Considerations in Antibiotic Treatment of Community-Acquired Pneumonia 139
8 ?-Lactams in the Therapy of Community-Acquired Pneumonia 165
9 Macrolides and Ketolides 183
10 Role of Fluoroquinolones in the Treatment of Community-Acquired Pneumonia 205
11 Non-Responding Pneumonia 225
12 Influenza and Pneumococcal Vaccination for Prevention of Community-Acquired Pneumonia in Immunocompetent Adults 241
13 Adjunctive Therapy in Community-Acquired Pneumonia 257
Index 275
Erscheint lt. Verlag | 31.7.2008 |
---|---|
Sprache | englisch |
Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Pneumologie |
Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung | |
Schlagworte | clinical microbiology • geriatric medicine • Geriatrie • Immunologie • immunology • Klinische Mikrobiologie • Medical Science • Medizin • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin |
ISBN-10 | 0-470-77278-6 / 0470772786 |
ISBN-13 | 978-0-470-77278-2 / 9780470772782 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 1,5 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich